Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

EGFR Gene Mutation Clinical Trial

Official title:
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma: A Randomized, Controlled, Open-label, Single-center Phase II Clinical Trial

Status Recruiting

Clinical Trial Summary

To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.

Clinical Trial Description

The best treatment for lung cancer is still radical resection, which is indicated for stage I-II and some stage III patients, but surgery is only suitable for 20-25% of NSCLC patients. Furmonertinib is a third-generation TKI drug. Compared with first and second-generation TKI drugs, it has good benefits in the Chinese population, patients with brain metastases, and patients with 19del/L858R mutation, with better and longer-lasting effects, and can significantly improve the progression-free survival of patients. Neoadjuvant therapy can shrink the tumor, increase the rate of complete surgical resection, remove micrometastases, and reduce the risk of recurrence. Cases of patients with locally advanced (IIIA-N2) NSCLC have been reported with neoadjuvant TKI therapy, and it has been found that neoadjuvant TKI therapy can downgrade or even complete tumor remission. However, for locally advanced potentially resectable, or EGFR mutation-positive NSCLC patients with single-organ metastasis, the efficacy of third-generation EGFR-TKI combined with VEFGR inhibitor combined with targeted therapy after induction and surgery is still unclear. Limited clinical research data suggest that this new treatment mode (induction therapy-surgery-adjuvant therapy) can significantly improve the progression-free survival of patients. However, the overall survival rate under the new treatment mode and the promotion of clinical work urgently need higher-level clinical evidence to support clinical decision-making. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05503667
Study type	Interventional
Source	Shanghai Pulmonary Hospital, Shanghai, China
Contact	Peng Zhang, MD,PhD
Phone	+8613512185932
Email	zhangpeng1121@outlook.com
Status	Recruiting
Phase	Phase 2
Start date	February 1, 2022
Completion date	December 31, 2028

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06071013` - Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients	Phase 1/Phase 2
Recruiting	`NCT05598528` - Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Recruiting	`NCT04042558` - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	Phase 2
Not yet recruiting	`NCT06018688` - Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.	Phase 2
Active, not recruiting	`NCT04013542` - Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer	Phase 1
Recruiting	`NCT05517083` - Feasibility of Intratumoral Washing Fluid for Detecting EGFR Mutations in Lung Cancer	N/A
Not yet recruiting	`NCT04592666` - Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer	Phase 2
Active, not recruiting	`NCT03065387` - Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	Phase 1
Completed	`NCT03653546` - First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases	Phase 2/Phase 3
Recruiting	`NCT03720873` - EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC	Phase 2
Active, not recruiting	`NCT02954523` - Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations	Phase 1/Phase 2
Active, not recruiting	`NCT03732352` - 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma	Phase 2
Completed	`NCT04552613` - Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients	N/A
Completed	`NCT03755102` - A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.	Early Phase 1
Recruiting	`NCT02338011` - Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)	Phase 2/Phase 3
Recruiting	`NCT04085315` - Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer	Phase 1
Not yet recruiting	`NCT06117644` - The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC
Recruiting	`NCT03396185` - Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer	Phase 2
Recruiting	`NCT03042221` - Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy